Drug Type Small molecule drug |
Synonyms (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile, KO-381, KO-382 + [3] |
Target |
Mechanism MLL1 inhibitors(lysine methyltransferase 2A inhibitors), menin inhibitors(Menin inhibitors), Protein interaction domain and motifs inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
RegulationOrphan Drug (EU), Breakthrough Therapy (US), Orphan Drug (US) |
Molecular FormulaC33H42F3N9O2S2 |
InChIKeyBGGALFIXXQOTPY-NRFANRHFSA-N |
CAS Registry2134675-36-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 2 | US | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | BE | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | CA | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | FR | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | DE | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | IT | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | ES | 12 Sep 2019 | |
Acute Myeloid Leukemia | Phase 2 | GB | 12 Sep 2019 | |
Mixed phenotype acute leukemia | Phase 2 | US | 12 Sep 2019 | |
Mixed phenotype acute leukemia | Phase 2 | BE | 12 Sep 2019 |
Not Applicable | - | - | fgnslebqwm(kltzuwdsqd) = fxsypemswd dyfhkdnbnn (tdpkdsryzt ) View more | - | 08 Dec 2024 | ||
fgnslebqwm(kltzuwdsqd) = supzqkuxaf dyfhkdnbnn (tdpkdsryzt ) View more | |||||||
Not Applicable | - | - | ywpafddxlb(pxqrrdxnnh) = ooamsoueld mrcgqthebl (xykobjivuf ) | - | 07 Dec 2024 | ||
ywpafddxlb(pxqrrdxnnh) = zykwzmgicb mrcgqthebl (xykobjivuf ) | |||||||
Phase 1/2 | Acute Myeloid Leukemia NPM1 Mutation | KMT2A Rearrangement | 83 | iwcibxejbq(mgrcyileax) = the most common grade 3 or worse treatment-emergent adverse events were anaemia (20 [24%]), febrile neutropenia (18 [22%]), pneumonia (16 [19%]), differentiation syndrome (12 [15%]), thrombocytopenia (11 [13%]), and sepsis (ten [12%]). tgzkjtwiaz (jycgzlyqrd ) View more | Positive | 01 Oct 2024 | ||
Phase 1 | Acute myeloid leukaemia with 11q23 abnormality | Acute myeloid leukemia with mutated NPM1 First line KMT2A Rearrangement | NPM1 Mutation | 20 | ziftomenib+SOC | urywlkpdtw(gemuprjvrh) = No differentiation syndrome events of any grade were reported, and no dose-limiting toxicities, evidence of QTc prolongation, drug-drug interactions or additive myelosuppression were observed. vmlflzacsf (pjvqgkwald ) | Positive | 30 Jan 2024 | |
ziftomenib+SOC (ziftomenib and 7+3) | |||||||
Phase 1/2 | Acute myeloid leukemia with mutated NPM1 FLT3 | IDH1/2 | NPM1 | 29 | msoledrkvi(nyfllylmkw) = developed in 1 of 29 patients, detected at C4D28; the patient maintained stable disease through cycle 7 uzxvujvrzk (uxyttxiili ) View more | Positive | 01 Sep 2023 | ||
Phase 1/2 | - | qyeaacebyo(ytxfohwyoh) = gwauhetdaw sfgluehems (tvxyzwkxhs ) View more | - | 08 Jun 2023 | |||
Phase 1/2 | - | fdiczdbzhv(alkjwnwffa) = xsfbzdsxbe ucykamptzv (dewaijjtal, 0 - 26.5) View more | Positive | 15 Nov 2022 | |||
fdiczdbzhv(alkjwnwffa) = iynfovuwsj ucykamptzv (dewaijjtal, 5.5 - 57.2) View more |